Sign in
IMRX Stock Price, Chart, Stats & News
Immuneering Corporation
Save
168.44M
Market cap
–
Current P/E
–
Forward P/E
IMRX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -24.15% |
ROE | -43.33% |
D/E | 0.02x |
Interest coverage ratio | – |
IMRX valuation
P/E | – |
P/S | – |
P/B | 1.00x |
P/CF | -4.81x |
P/FCF | -3.96x |
P/OCF | -4.81x |
PEG | -0.17x |
EV multiple | -5.20x |
About
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors.
Similar securities
Based on sector and market capitalization
Report issue